Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and recommended Phase 2 dose (RP2D) of MK-0482. There are 2 parts of this study. Part 1 is a dose escalation which will follow an accelerated titration design (ATD). Part 2 is a dose expansion in the same relapsed/refractory (R/R) AML subtypes as in Part 1.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05038800
Study type Interventional
Source Merck Sharp & Dohme Corp.
Status Not yet recruiting
Phase Phase 1
Start date October 6, 2021
Completion date September 29, 2025

See also
  Status Clinical Trial Phase
Terminated NCT04478695 - Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia Phase 1
Active, not recruiting NCT04176393 - A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation Phase 1
Recruiting NCT04666649 - Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) Phase 1
Recruiting NCT04842370 - Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AML Phase 1
Recruiting NCT02675452 - AMG 176 First in Human Trial in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia Phase 1
Recruiting NCT03765541 - Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia Phase 3
Terminated NCT02623582 - CD123 Redirected Autologous T Cells for AML Early Phase 1
Withdrawn NCT02215629 - Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia Phase 1